Emerging facade of menopausal hormone therapy.
Menopausal hormone therapy (HT) has been around for 70 years, and in the 1980s and 1990s was considered a universal panacea for women's problems from midlife onward. However, this concept was challenged by the results of the Women's Health Initiative (WHI) and the Million Women Study (MWS) that were first published in 2002 and 2003. Since the publication of these studies, prescriptions of HT have markedly declined and there have been many media scares. An unfortunate sequel was an extrapolation of the observations from women in their 50s and older to those with early ovarian failure. This article discusses the WHI and the MWS with a focus on differences between HT regimens including doses, formulations, and routes, timing, and duration of HT. It addresses practical issues such as strategies for stopping HT, and discusses bioidentical hormones. The specialist knowledge now required to deliver post-reproductive health service has led to considerations that menopause management should be now the responsibility of a specialist and not a general gynecologist.
Rees
Margaret
M
Reproductive Medicine, University of Oxford, Oxford, United Kingdom. margaret.rees@obs-gyn.ox.ac.uk
D000368:Aged; D015914:Estrogen Replacement Therapy / Q000009:adverse effects* / Q000379:methods / Q000639:trends*; D005260:Female; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D012306:Risk; D016387:Women's Health; D014932:Women's Health Services